Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...
For example, Nvidia owns stakes in six smaller companies. I think Recursion Pharmaceuticals (RXRX 3.62%) is arguably the most intriguing of the group. Recursion looks like a big dud so far. The ...
Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...
Md has been working as a game journalist for the past seven years and has written for Screen Rant, DualShockers Game Pur, Spiel Times, and several other leading media outlets across the world. Also, ...
Organisations using Java face a licence fee hike after Oracle’s introduction of subscription pricing for Java SE. Analyst Forrester has previously written that the move to what Oracle calls the Java ...
AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...
After a year defined by pipeline cuts, the departure of its CEO and layoffs, Exscientia will merge into Recursion, creating one company that has 10 clinical readouts to look forward to over the next ...
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
Can Recursion accelerate the time frame for drug discovery? Last year, Recursion announced that tech giant Nvidia invested $50 million into its operations. Together, the businesses are working on drug ...
Artificial intelligence (AI)-based drug developer Recursion said it has completed the fastest supercomputer to be wholly owned and operated by any pharmaceutical company worldwide, using technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results